For the treatment of plaque psoriasis in adults
For the treatment of plaque psoriasis in adults

A unique new topical treatment

Wynzora is the first and only once-daily topical calcipotriene and betamethasone diproprionate (Cal/BDP) cream powered by PAD™ Technology, which works to clear plaques without the messiness of conventional formulations1-4

Proprietary PADTM Technology

Using PADTM Technology, Wynzora gently infuses the skin with Cal/BDP in a fast-absorbing, water-based cream designed to encourage patient adherence1

Efficacy

In a head-to-head study, 37.4% of Wynzora patients were clear or almost clear by week 83

Safety

Only 1% of Wynzora patients experienced application-site irritation3

Convenience

When measured against a Cal/BDP topical suspension, the moisturizing, water-based formulation of Wynzora achieved greater convenience scores1

Eligible patients may pay as little as

*At participating pharmacies. Limitations apply. Reduced copay for commercially insured eligible patients. Uninsured and government-insured patients are not eligible for these offers. See rebate card for details.

GET UPDATES ON WYNZORA

*Required fields.

I authorize MC2 Therapeutics, EPI Health, and companies working with MC2 Therapeutics and EPI Health to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about their products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by MC2 Therapeutics, EPI Health, and companies working with MC2 Therapeutics and EPI Health to help develop new products, services, and programs. I understand that my consent is not required as a condition of receiving any product information or services from MC2 Therapeutics and/or EPI Health. MC2 Therapeutics, EPI Health, and companies working with MC2 Therapeutics and EPI Health will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission.
I agree to the statement above and have read and understand the Terms and Conditions and Privacy Policy.
arrow

Indication and Use

Wynzora® (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis in adults. It is not known if Wynzora Cream is safe and effective in children.

Important Safety Information

  • Wynzora Cream is for topical use only.
  • Patients should not use more than 100g of Wynzora Cream per week.
  • Wynzora Cream should not be used near or in the mouth, eyes, or intravaginally.
  • Patients should avoid using Wynzora Cream on the face, groin, or armpits, or if they have atrophy at the treatment site.
  • Patients should apply Wynzora Cream to the affected areas of the skin once a day for up to 8 weeks.
  • Patients should discontinue use once the plaque psoriasis is under control.
  • Patients should not use with occlusive dressings.
  • Hypercalcemia and hypercalciuria have been observed with use of topical calcipotriene.
  • Wynzora Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment.
  • Wynzora Cream may cause vision problems, including increasing the risk of cataracts and glaucoma.
  • It is not known whether Wynzora Cream may harm your unborn baby.
  • Breastfeeding women should not apply Wynzora Cream directly to the nipple and areola.
  • It is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Præstegaard M, Vestbjerg B, Selmer J, Holm-Larsen T. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62. 2. US Department of Health and Human Services. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 41st ed. US Government Publishing Office; 2021. https://www.fda.gov/media/71474/download. Accessed April 21, 2021. 3. Wynzora® Cream [package insert]. MC2 Therapeutics; 2020. 4. MC2 Therapeutics. PAD™ Technology. https://padcream.com/. Accessed February 19, 2021.